Dr. Tanya Simuni joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build a multidisciplinary movement disorders center that is recognized by the Parkinson’s Foundation, Huntington Disease Society of America and Wilson’s Foundation as a Center of Excellence and serves as a training model in the region. She is the lead investigator for a number of clinical trials on experimental pharmacology, non-motor manifestations and pharmacological management of Parkinson’s disease (PD). She serves on a number of committees for PD national clinical trials, the Parkinson Study Group (PSG) and the Parkinson’s Foundation. She is the site PI for the largest PD biomarker initiative (PPMI study) and for the Network for Excellence in Neuroscience Clinical Trials (NEXT). Dr. Simuni is an active member of the American Academy of Neurology, American Neurological Association, the Movement Disorders Society as well as the PSG.
Associated Grants
-
Objectively Measuring the Severity of Vocal and Speech-related Symptoms Associated with Parkinson’s Disease
2022
-
Phase IIa Safety and Tolerability Trial of Nilotinib in People with Parkinson's Disease
2017
-
-
High Resolution Diffusion Tensor MRI Imaging as a Biomarker of Parkinson's Disease Diagnosis and Disease Progression
2009